Depletion of central memory CD8+ T cells might impede the antitumor therapeutic effect of Mogamulizumab - Maeda, Yuka; Wada, Hisashi; Sugiyama, Daisuke; Saito, Takuro; Irie, Takuma; Itahashi, Kota; Minoura, Kodai; Suzuki, Susumu; Kojima, Takashi; Kakimi, Kazuhiro; Nakajima, Jun; Funakoshi, Takeru; et al. (Nature communications, 2021)
Keywords: 13/31; 631/250/251/1574; 631/67/580/1884/2323; 692/4017; 692/4028/67/1059/2325; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized - therapeutic use; Anticancer properties; Antineoplastic Agents - therapeutic use; Antitumor activity; Cancer; CD8 antigen; CD8-Positive T-Lymphocytes - drug effects; CD8-Positive T-Lymphocytes - metabolism; Cell differentiation; Chemokine receptors; Depletion; Dose-Response Relationship, Drug; Effector cells; Female; Homeostasis; Humanities and Social Sciences; Humans; Immune response; Immune system; Immunological memory; Immunoregulation; Immunotherapy; Killer Cells, Natural - drug effects; Killer Cells, Natural - metabolism; Lymphocytes; Lymphocytes T; Male; Memory cells; Memory T Cells - drug effects; Middle Aged; Monoclonal antibodies; multidisciplinary; Neoplasms - drug therapy; Neoplasms - immunology; Patients; Phenotypes; Receptors, CCR4 - antagonists & inhibitors; Receptors, CCR4 - metabolism; Science; Science (multidisciplinary); Solid tumors; T-Lymphocytes, Regulatory - drug effects; T-Lymphocytes, Regulatory - metabolism; Targeted cancer therapy; Treatment Outcome